Author Archive: Jason Corum

Jason Corum

Jason is the director of web and new media with the Biotechnology Industry Organization (BIO). Prior to joining BIO in March 2011, he was the online communications manager for World Food Program USA and an online communications specialist with the Brookings Institution.

Jason is originally from Evergreen Park, Ill. and still thinks that Chicago is the best food city in the nation.  He spends his free time volunteering with the DC Books to Prisons Project, watching movies and reading comics.

Latest Posts

NIH: Streamlining the Technology Transfer Process

cyclotron

The National Institutes of Health (NIH) is launching the electronic Research Materials catalogue (eRMa) to streamline the federal government’s technology transfer process. “To stay competitive in today’s world, on-line ordering is a requirement. With the launch of this first-of-its kind system, OTT is demonstrating its intention to meet that challenge,” said Mark Rohrbaugh, director of OTT. According to the press release: “The new system will streamline the licensing process by: Providing a website for companies Read More >

Public Policy  |  Leave a comment  |  Email This Post
Tags: , ,

Developing Cancer Therapies and Diagnostics: 4 Pieces of Advice

oncology

Insights in to the molecular and genetic basis of disease are driving new product and therapeutic opportunities while changing the treatment paradigm for many cancers. The use of companion diagnostics in oncology may play a role in optimizing and expediting the development of targeted therapies for many cancers and other conditions. Focusing on these new markets, a panel of industry executives and investors at the 2011 BIO Investor Forum discussed some of the most compelling Read More >

Health  |  1 Comment  |  Email This Post
Tags: , , , , , , ,

Reverse Mergers: A Company is Ready to Go Public, or it’s Not

The latest IPO window has stalled. There have been five IPO withdrawals since June and around 30 since 2005. Global macro events are threatening to completely shut it. Reverse mergers have become an increasingly popular option with eight transactions in the last year. Unfortunately, 47 percent of reverse mergers have decreased in value post-close since 2008. At the 2011 BIO Investor Forum, a panel of experts examined the current financing environment and what private executive Read More >

Business of Biotech  |  2 Comments  |  Email This Post
Tags: , , , ,

Increasing Partnering at BIO

Partnering Meetings

Mike May from Biotech Tallies writes: At the 2011 BIO International Convention, the number of one-on-one partnering meetings soared to 21,183… The increasing number of such meetings probably reflects the growth in biotechnology, the escalating importance of BIO’s annual meeting and the expanding need to partner for success in this field.

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , ,

Stopping ALS: An interview with Dr. Perrin from ALS TDI

thumb

What is ALS? How widespread is the disease? Are there any treatments for ALS? Amyotrophic lateral sclerosis (ALS), commonly known as Lou Gehrig’s disease and outside the US as Motor Neuron Disease (MND) or Charcot’s Disease, is a progressive neurodegenerative disease that attacks motor neurons in the brain (upper motor neurons) and spinal cord (lower motor neurons) and affects muscle function. Dr. Steven Perrin is the CEO, CSO and Vice Chairman of the ALS Therapy Read More >

Health  |  1 Comment  |  Email This Post
Tags: , , , ,